On July 15, 2021, Zenith presented at the Epigenetic Therapeutic Targets digital event
"Clinical Development of The BET Bromodomain Inhibitor ZEN-3694 In Solid Tumors: Lessons Learned"
• Design of epigenetic combinatorial therapies
• Clinical activity in breast and prostate cancer patients
• Mechanisms of action: similarities and differences between the prostate
and breast cancer trials
On April 10, 2021, Zenith Epigenetics presented at the AACR Annual Meeting 2021 - Virtual, the following poster: "Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status."
On April 29, 2021, Zenith Epigenetics presented at the Triple Negative Breast Cancer Drug Development Digital Summit 2021, the following: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations."
On July 28, 2020, Zenith participated in the Epigenetic Therapeutic Targets Virtual Summit, with an oral presentation by Dr. Eric Campeau, titled: "Design of combination strategies and identification of biomarkers associated with clinical response to ZEN-3694 in combination with enzalutamide in mCRPC." The presentation PDF can be accessed HERE.
Zenith will be participating at the American Association for Cancer Research (AACR) Virtual Meeting II from June 22 - 24, 2020. E-Poster titled: "Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer." The Poster can be accessed HERE.